# A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

> **NCT06951464** · PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 40 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** Almonertinib

## Key facts

- **NCT ID:** NCT06951464
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2027-05-05
- **Final completion:** 2029-03-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06951464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06951464, "A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06951464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*